Clinical Trials
Petosemtamab + Docetaxel as 2nd line treatment with metastatic NSCLC
Disease Type: Lung
A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Combination with Docetaxel as Second-Line Treatment in Adults with Metastatic Non-Small Cell Lung Cancer or in Combination with Pembrolizumab as First-Line Treatment
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville